Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gyre Therapeutics, Inc. - Common Stock
(NQ:
GYRE
)
8.580
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gyre Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 29, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday
May 27, 2025
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
May 23, 2025
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
May 23, 2025
Via
Benzinga
Let's take a look at the stocks that are in motion in today's session.
May 23, 2025
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
May 23, 2025
Via
Benzinga
Discover the top movers in Friday's pre-market session.
May 23, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
May 22, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
May 22, 2025
Via
Benzinga
Thursday's after hours session: top gainers and losers
May 22, 2025
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
May 22, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
May 22, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 12, 2025
Via
Benzinga
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 09, 2025
Net Income of $3.7 million; reaffirms Full-Year Revenue Guidance of $118–$128 million
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 14, 2025
Via
Benzinga
Discover the top movers in Monday's pre-market session.
April 07, 2025
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 07, 2025
Via
Benzinga
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday
April 02, 2025
Via
Benzinga
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
March 31, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
March 27, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge
March 18, 2025
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 18, 2025
Via
Benzinga
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 17, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 13, 2025
Via
Benzinga
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
January 06, 2025
From
Gyre Therapeutics, Inc.
Via
GlobeNewswire
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
November 13, 2024
From
Gyre Therapeutics, Inc.
Via
GlobeNewswire
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
October 22, 2024
From
Gyre Therapeutics, Inc.
Via
GlobeNewswire
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
October 01, 2024
From
Gyre Therapeutics, Inc.
Via
GlobeNewswire
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday
September 18, 2024
Via
Benzinga
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Gyre Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.